Emory University has created an endowed distinguished professorship honoring George Painter for his life-saving work in developing critical medicines including molnupiravir, which is now approved globally for the treatment of SARS-CoV-2.
Emory University has created an endowed distinguished professorship honoring George Painter for his life-saving work in developing critical medicines including molnupiravir, which is now approved globally for the treatment of SARS-CoV-2.
Faculty entrepreneurs and their discoveries were recognized at the Office of Technology Transfer’s 16th Annual Celebration of Technology and Innovation. Three new awards were added this year, for a total of seven categories.
Researcher and inventor Dennis Liotta is the 2022 recipient of the Perkin Medal, the highest honor a scientist can receive for contributions to applied chemistry in the U.S. His discoveries include transformative treatments for HIV and hepatitis B.
The drug’s journey from a university lab is latest example of the unlikely sources of pandemic antidotes.
On Dec. 23, molnupiravir, an investigational oral antiviral drug invented by scientists at Emory University, received Emergency Use Authorization from the FDA for the treatment of COVID-19.
From research breakthroughs to a Rhodes Scholar, faculty, students and staff found many ways to flourish in 2021. Take a look back at 10 of the biggest stories, with more headlines so you can delve deeper into this year of impact and achievement.
A FDA panel voted in favor of a proposed Emergency Use Authorization for the antiviral drug molnupiravir.
AJC: Emory-developed COVID drug seeks FDA approval
CNN: The FDA will soon decide on Merck's Covid-19 antiviral pill. It shows promise, but there are also concerns
AJC: Opinion: Public engagement: The next scientific revolution
Washington Post: Britain authorizes Merck’s molnupiravir, the world’s first approval of oral covid-19 treatment pill
Associated Press: UK authorizes Merck antiviral pill, 1st shown to treat COVID
Wall Street Journal: Merck COVID-19 pill cleared for use in UK, its first authorization
An Emory-invented antiviral treatment for COVID-19 has been authorized by British regulators, making molnupiravir the first antiviral pill approved for use against SARS-CoV-2. An emergency use application is also under consideration by the U.S. Food and Drug Administration.
BioSpace: Merck’s molnupiravir: When a private-public partnership bears fruit
The Medicines Patent Pool and Merck have entered into a licensing agreement to facilitate affordable access for molnupiravir, an investigational oral antiviral COVID-19 medicine, in 105 low- and middle-income countries.
With Merck’s findings that Emory-discovered molnupiravir may significantly reduce the risk of hospitalization or death from COVID-19, Emory President Gregory L. Fenves joins epidemiologist Jodie Guest in a conversation about Emory’s history of research innovation.
USA TODAY: Drugmakers seek FDA emergency authorization for molnupiravir, antiviral pill to treat COVID-19: Latest updates
Nature: How antiviral pill molnupiravir shot ahead in the COVID drug hunt
Wall Street Journal: Pill intended to be COVID-19’s Tamiflu succeeds in key study
WXIA/11Alive: First pill to treat COVID, now headed for approval process, was discovered by Emory researchers
Gizmodo: Merck and Ridgeback say their COVID-19 pill cuts chance of hospitalization and death by half
USA TODAY: New antiviral is highly effective, study finds, and is stirring hope that COVID-19 could be treated by a pill
Contagion Live: Molnupiravir could become the first authorized COVID-19 pill
Daily Mail: Merck says its experimental COVID-19 pill cut hospitalizations and deaths by HALF in people recently infected with the virus - and plans to apply for FDA approval
BioPharma Dive: Merck says antiviral pill effective against COVID-19, lifting hopes for first oral drug
STAT: Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment
NPR: Merck to seek emergency authorization for pill it says cuts COVID-19 effects
The Scientist: Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial
Chemistry World: Where are the COVID-19 drugs?
Bloomberg: Merck’s COVID pill changes drugmaker’s fate after failed shots
ABC News: New COVID-19 pills may keep recently diagnosed patients out of hospital, company says
AJC: Emory University research helps develop potential COVID-19 treatment drug
GPB: Promising COVID pill cuts hospitalizations and death in half. Atlanta's Emory University invented it
CNN: A pill to treat Covid-19: 'We're talking about a return to, maybe, normal life'
ScienceDirect: Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
Molnupiravir, an investigational oral antiviral drug discovered by Emory researchers, appears to significantly reduce the risk of hospitalization or death in patients with mild to moderate COVID-19, according to interim data from a Phase 3 study.
Kaiser Health News: A daily pill to treat COVID could be just months away, scientists say
medRxiv: Molnupiravir, an oral antiviral treatment for COVID-19
New York Times: The U.S. will spend $3 billion on developing antiviral pills to treat Covid-19
Business Wire: Merck announces supply agreement with U.S. government for molnupiravir, an investigational oral antiviral candidate for treatment of mild to moderate COVID-19
PBS News Hour: Scientists hope they’re closing in on a cure for COVID-19
The Economic Times: Seeking a pill to cure Covid: drugmakers eye alternative to vaccines
Global Atlanta: Merck to license Emory antiviral drug to combat India’s COVID-19 surge
MedPage Today: How molnupiravir moved to the head of the 'COVID pill' pack
To address the intensifying COVID-19 crisis in India, the pharmaceutical company Merck has agreed to facilitate the manufacture and distribution of molnupiravir, an investigational antiviral drug that was discovered at Emory.
Bloomberg Businessweek: Merck’s little brown pill could transform the fight against COVID
An antiviral drug initially discovered by Emory’s non-profit drug development company DRIVE appears safe and reduces SARS-CoV-2 to undetectable levels in COVID-19 patients after five days of administration, according to data from a Phase II clinical trial.
Nature: SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
An oral antiviral discovered and developed at Emory can begin human trials. EIDD-2801 has shown promise for treating COVID-19.
Scientists are hopeful that a new drug called EIDD-2801 could change the way doctors treat COVID-19. The drug shows promise in reducing lung damage and has finished testing in mice. It will soon move to human clinical trials.
Chemical and Engineering News: Emory-discovered antiviral is poised for COVID-19 clinical trials
Ridgeback Biotherapeutics will license EIDD-2801, a potential drug against coronaviruses, from Emory's DRIVE and take it through clinical trials.
Drug Innovation Ventures at Emory is developing an antiviral compound, discovered here, that could potentially treat the new coronavirus currently spreading around the globe.